Product nameAnti-Melusin antibody [EPR13537]
See all Melusin primary antibodies
DescriptionRabbit monoclonal [EPR13537] to Melusin
Tested applicationsSuitable for: WBmore details
Unsuitable for: ICC/IF,IHC-P or IP
Species reactivityReacts with: Human
Synthetic peptide within Human Melusin aa 300 to the C-terminus (C terminal) (Cysteine residue). The exact sequence is proprietary.
Database link: Q9UKP3
- Human fetal heart and Human skeletal muscle lysates.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Previously labelled as ITGB1BP2.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab180858 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/5000. Predicted molecular weight: 38 kDa.|
RelevanceMelusin is a muscle-specific protein that interacts with the Integrin 1 cytoplasmic domain, in the hypertrophic response to mechanical overload.
Cellular localizationPlasma membrane
- CHORDC3 antibody
- Integrin beta 1 binding protein (melusin) 2 antibody
- integrin beta 1 binding protein 2 antibody
ab180858 has not yet been referenced specifically in any publications.